← Back to headlines
Monod Bio Licenses AI-Designed Protein Technologies to SignalChem Biotech
Monod Bio has entered a licensing agreement with SignalChem Biotech to utilize its AI-designed protein technologies for custom discovery assays.
26 Aug, 12:33 — 26 Aug, 12:33
Related Stories
CrowdStrike raises annual revenue forecast on strong cybersecurity demand - The Star
13m ago
South Korea Central Bank Raises Rates to 3%, Upgrades Growth Forecast
30m ago
Meta Agrees to $17 Billion Settlement Over Teen Mental Health Lawsuits
58m ago
Nvidia in Talks to Acquire AI Platform Hugging Face for Over $13 Billion
1h ago